Drug Profile
Calcium aluminium silicate - Salient Pharmaceuticals
Alternative Names: Aluminium calcium silicate; Aluminum calcium silicate; Calcium alumina-silicate; Calcium aluminosilicate; Calcium aluminosilicate anti-diarrheal; Calcium aluminosilicate anti-diarrhoeal - Salient Pharmaceuticals; Calcium aluminum silicate; Calcium silicoaluminate; CASAD; Silicate cement; Silicic acid aluminium calcium salt; Silicic acid aluminum calcium saltLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Salient Pharmaceuticals
- Developer Salient Pharmaceuticals; University of Texas M. D. Anderson Cancer Center
- Class Aluminium compounds; Antidiarrhoeals; Calcium compounds; Noncarboxylic acids
- Mechanism of Action Cytokine inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Clostridium difficile infections; Diarrhoea; Inflammatory bowel diseases; Proctitis; Stomatitis
Most Recent Events
- 19 Apr 2016 No recent reports on development identified - Phase-II for Diarrhoea (Chemotherapy-induced) in USA (PO)
- 19 Apr 2016 No recent reports on development identified - Preclinical for Clostridium difficile infections in USA (PO)
- 19 Apr 2016 No recent reports on development identified - Preclinical for Inflammatory bowel disease in USA (PO)